GlycoSyn strikes $14 million deal with Ginkgo Bioworks to broaden the reach of its human milk oligosaccharides (HMOs) platform

November 8, 2018
Accelerating Materials Innovation More...
Prebiotics | Synthetic biology
Investment More...
10085 thumb square
by Thomas Hayes
Very important

Just two months ago, we predicted that HMOs would be a high-growth area for prebiotics, and this event certainly supports that. After obtaining EU regulatory approval for production of 2'-fucosyllactose (2'-FL) in partnership with FrieslandCampinaGlycoSyn is looking to use this deal with Ginkgo Bioworks to lead the race against Jennewein Biotechnologie and DuPont/Inbiose to produce HMOs beyond 2'-FL. From Ginkgo's perspective, this adds a new twist to its business model – providing direct investment and foundry access to smaller companies. Assuming Ginkgo will continue doing this, clients should seek out Ginkgo as a resource to help optimize strain design for fermentation products of interest from startups and SMEs.

For the original news article, click here .

Further Reading

Zymergen raises $400 million Series C

News Commentary | December 13, 2018

Zymergen had previously focused on improving its clients' strains – claiming scales over 100,000 tpa for strains and producing on the order of $100 million worth of product per year. Not only will Zymergen use this funding to double the capacity of its platform, but it also intends to use the ... To read more, click here.


Company Profile | April 12, 2018

Combines predictive computational modeling tools, microorganism design and development, and process engineering to develop fermentation‑based production routes; modeling of the fermentation process decreases the amount of test runs before scale‑up, reducing the time and cost to develop new ... Not part of subscription

Synthetic Biology

Technology | May 29, 2018

Technologies to create new organisms, including microbes and plants, with valuable capabilities for various applications. Not part of subscription